Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleMETABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction

Scott G. Summerfield, Kevin Read, David J. Begley, Tanja Obradovic, Ismael J. Hidalgo, Sara Coggon, Ann V. Lewis, Rod A. Porter and Phil Jeffrey
Journal of Pharmacology and Experimental Therapeutics July 2007, 322 (1) 205-213; DOI: https://doi.org/10.1124/jpet.107.121525
Scott G. Summerfield
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Read
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Begley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanja Obradovic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ismael J. Hidalgo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Coggon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann V. Lewis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rod A. Porter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Phil Jeffrey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

This article has a correction. Please see:

  • Correction to “Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction” - September 01, 2009

Abstract

The dispositions of 50 marketed central nervous system (CNS) drugs into the brain have been examined in terms of their rat in situ (P) and in vitro apparent membrane permeability (Papp) alongside lipophilicity and free fraction in rat brain tissue. The inter-relationship between these parameters highlights that both permeability and brain tissue binding influence the uptake of drugs into the CNS. Hydrophilic compounds characterized by low brain tissue binding display a strong correlation (R2 = 0.82) between P and Papp, whereas the uptake of more lipophilic compounds seems to be influenced by both Papp and brain free fraction. A nonlinear relationship is observed between logPoct and P over the 6 orders of magnitude range in lipophilicity studied. These findings corroborate recent reports in the literature that brain penetration is a function of both rate and extent of drug uptake into the CNS.

Footnotes

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.107.121525.

  • ABBREVIATIONS: CNS, central nervous system; BBB, blood-brain barrier; P, in situ brain permeability; Papp, apparent membrane permeability; fu(brain), in vitro free fraction in brain tissue; clogPoct, log octanol/water partition coefficient; MDR, multidrug resistance; MDCK, Madin-Darby canine kidney; PBS, phosphate-buffered saline; TEER, transepithelial electrical resistance; P-gp, P-glycoprotein; HPLC, high-performance liquid chromatography; MS/MS, tandem mass spectrometry; GF120918A, N-(4-{2-[6,7-bis(methyloxy)-3,4-dihydro-2(1H)-isoquinolinyl]ethyl}phenyl)-5-(methyloxy)-9-oxo-9,10-dihydro-4-acridinecarboxamide hydrochloride.

  • ↵ Embedded Image The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.

    • Received February 15, 2007.
    • Accepted April 2, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 385 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 385, Issue 1
1 Apr 2023
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleMETABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction

Scott G. Summerfield, Kevin Read, David J. Begley, Tanja Obradovic, Ismael J. Hidalgo, Sara Coggon, Ann V. Lewis, Rod A. Porter and Phil Jeffrey
Journal of Pharmacology and Experimental Therapeutics July 1, 2007, 322 (1) 205-213; DOI: https://doi.org/10.1124/jpet.107.121525

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleMETABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction

Scott G. Summerfield, Kevin Read, David J. Begley, Tanja Obradovic, Ismael J. Hidalgo, Sara Coggon, Ann V. Lewis, Rod A. Porter and Phil Jeffrey
Journal of Pharmacology and Experimental Therapeutics July 1, 2007, 322 (1) 205-213; DOI: https://doi.org/10.1124/jpet.107.121525
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • HDL Mimetic 4F Modulates Aβ Distribution in Brain and Plasma
  • AOX1 Inhibition by Gefitinib, Erlotinib, and Metabolites
  • Catalytic Activity of CYP2C9 Variants
Show more Metabolism, Transport, and Pharmacogenomics

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics